Real Patient Data, Real Results
Every number below comes from validated clinical assessments administered to real patients. No estimates, no projections — just data.
How Ibogaine Resets the Brain
Ibogaine acts on six distinct neural pathways simultaneously — no other known substance has this breadth of action.
Cardiac Monitoring: Zero Mortality
QTc prolongation is the primary cardiac risk of ibogaine. Our AI monitors every heartbeat in real time.
What Our AI Discovers
No other ibogaine clinic has 947+ structured patient outcomes feeding an AI analysis engine. Here's what it's found.
QTc Trend Analysis
Real-time cardiac monitoring with automated alert thresholds. Predicts QTc trajectory from baseline vitals with 94% accuracy.
Dose Optimization
Weight-adjusted dosing curves personalized per patient profile. Our AI identified the 0.20–0.22 mg/kg sweet spot delivering 81–86% COWS reduction.
Risk Scoring
Predictive adverse event risk scoring from baseline assessments. Flags high-risk patients before treatment begins.
Outcome Forecasting
Projects treatment trajectory from intake data. Helps set realistic expectations and customize protocol intensity.
Protocol Refinement
Continuous multi-scale outcome aggregation discovers what works. Found that day 3-5 boosters improve 30-day retention by 23%.
Research Synthesis
Scans 147+ published studies cross-referenced against our clinical dataset. Identifies gaps between literature and real-world outcomes.
5 Findings That Changed Our Protocols
Weight-adjusted dosing outperforms fixed dosing by 23%
mg/kg calculations produce more consistent COWS reductions across all weight classes.
HCL formulation: 8.7% better outcomes, 56% less emesis than TA
Ibogaine HCL offers more predictable pharmacokinetics and fewer gastrointestinal side effects.
QTc delta from baseline predicts cardiac risk 2.4x better than absolute QTc
Individual change matters more than static thresholds — reshaping how we think about cardiac safety.
Dual diagnosis (OUD + PTSD) patients show 12% higher improvement
Treating both conditions simultaneously yields significantly better results than sequential approaches.
Day 3-5 booster doses improve 30-day retention by 23%
Small supplemental doses during the integration window extend the anti-craving effect through the critical first month.
HCL vs TA: Formulation Comparison
Head-to-head data from 1,203 treatment sessions
| Metric | Ibogaine HCL | Total Alkaloid (TA) |
|---|---|---|
| Doses Administered | 847 | 356 |
| COWS Reduction | 81.3% | 74.8% |
| Emesis Rate | 12.4% | 28.1% |
| Re-dose Rate | 8.7% | 15.3% |
| Avg Resolution Time | 14.2 hours | 18.6 hours |
Data-Driven Treatment Starts Here
947 patients have generated the evidence. Our AI has found the patterns. Now it's your turn to benefit from the most data-informed ibogaine protocol on earth.